Deva
DEVA Holding A.Ş. is a vertically integrated Turkish pharmaceutical manufacturer founded in 1958 that produces APIs and finished dosage forms across 15 therapeutic areas, exporting through ten Devatis subsidiaries to 80+ countries with 1,863 product registrations in 86 markets.
- Company typePublic
- Founded1958
- HeadquartersIstanbul
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Deva does
DEVA Holding A.Ş. is a vertically integrated Turkish pharmaceutical manufacturer founded in 1958 and headquartered in Istanbul. The company produces both active pharmaceutical ingredients (APIs) and finished dosage forms across 15 therapeutic areas, including cardiology, oncology, respiratory, hematology, dermatology/immunology, central nervous system, and musculoskeletal segments. Manufacturing is concentrated at four Turkish facilities: Çerkezköy-I (52,000 m²) for liquids, semi-solids, cephalosporins, penicillins, hormones, inhalation products, sterile ampoules/vials, and softgels; Çerkezköy-II (67,551 m²) for high-potency oncology, sterile liquids, animal health, API manufacturing, and the integrated biotechnology and R&D buildings; Kartepe (32,000 m²) for sterile liquids, ampoules, and cologne products; and Çerkezköy-IV, a 58,000 m² logistics center with 43,500-pallet capacity. Combined production capacity exceeds 620 million units annually.
The business model combines B2B product sales, contract manufacturing services, API exports, and licensing/co-development with international partners. Revenue is generated across multiple streams: sales of human pharmaceuticals, APIs, veterinary medicines, and consumer products (including cologne under Boğaziçi Kolonyaları). International reach is executed through ten wholly-owned Devatis subsidiaries in the US, Germany, UK, Switzerland, Netherlands, Canada, Mexico, Australia, and Serbia, supported by a network-based order-to-cash model (TraceLink MINT) in the US. Distribution extends to 80+ countries, with 1,863 product registrations across 86 countries including highly regulated markets. Customers include healthcare professionals, patients, and international pharmaceutical manufacturers using DEVA for contract manufacturing and API supply. Pricing is quote-based and not publicly disclosed; products are sold B2B via wholesalers, 3PLs, and direct distribution. The company is publicly listed on the Istanbul Stock Exchange under ticker DEVA, is majority-controlled by EastPharma Ltd., and reports under Chairman/CEO Philipp Haas.
Technology and R&D are anchored by the DEVARGE center, which employs 400+ researchers across pharmaceutical development, analytical development, API development, biotechnology, biosimilars, bioequivalence, and CMC documentation. Facilities operate under US FDA, EU GMP, ISO 9001, ISO 14001, ISO 45001, ISO 27001, and ISO 50001 certifications, with a UN registered-supplier status. Notable capabilities include Blow-Fill-Seal (BFS) sterile manufacturing, high-containment oncology production with isolator technology, and biosimilar development infrastructure. Workforce is 3,000+, with 219,660 hours of annual training and a Lost Time Injury Frequency Rate of 0.66.
Deva firmographics
Firmographics- Name
- Deva
- Legal name
- DEVA HOLDİNG ANONİM ŞİRKETİ
- Website
- https://deva.com.tr
- Company type
- Public
- Founded year
- 1958
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- DEVA Holding A.Ş. is a vertically integrated Turkish pharmaceutical manufacturer founded in 1958 that produces APIs and finished dosage forms across 15 therapeutic areas, exporting through ten Devatis subsidiaries to 80+ countries with 1,863 product registrations in 86 markets.
- Ownership category
- akta.pro rank
Deva industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)
- akta.pro secondary industries
- Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
Keywords
Where Deva is headquartered
LocationHeadquarters
- HQ city
- Istanbul
Offices5 records
Markets served
Deva business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Pharmaceutical Products: Manufacturing and sale of pharmaceutical products across 15 therapeutic areas including human pharmaceuticals, API production, veterinary medicines, and consumer health products. Products distributed through international network to 80+ countries.
- Contract Manufacturing Services: High-quality contract manufacturing services provided to international partners in line with global quality standards including US FDA and EU GMP compliant facilities.
- Active Pharmaceutical Ingredients (API): Supply of active pharmaceutical ingredients developed in modern manufacturing facilities to pharmaceutical manufacturers worldwide, leveraging vertically integrated structure.
- Licensing and Co-development: Through licensing agreements with international partners, expansion of product portfolio into new markets and development collaborations that create mutual value. Leveraging R&D capabilities for co-development of new pharmaceutical products.
Go-to-market motion2 records
Distribution channels5 records
Marketing channels5 records
Deva product offering
Product offeringCore offering
DEVA Holding is a vertically integrated pharmaceutical manufacturer that develops, produces, and markets human pharmaceuticals across 15 therapeutic areas, active pharmaceutical ingredients (APIs), veterinary medicines, and consumer health products. The company operates four manufacturing facilities compliant with US FDA and EU GMP standards, conducts R&D through its DEVARGE center with 400+ researchers, and exports products to 60+ countries with 1,863 product registrations across 86 countries. Additional revenue lines include contract manufacturing services and licensing/co-development partnerships with international pharmaceutical firms.
Product overview
Deva Holding operates as a diversified pharmaceutical company with a portfolio of sub-brands including DEVA (core pharmaceutical products), Saba (consumer healthcare), Devatis (international operations), Vetas (animal health), and Boğaziçi Kolonyaları (consumer products). The company is organized around four main business segments: human pharmaceuticals with 15 therapeutic areas covering cardiopulmonary, cardiovascular, central nervous system, dermatology/immunology, musculoskeletal, oncology/hematology, respiratory, sensory organs, blood products, digestive/metabolism, genitourinary/sex hormones, systemic hormonal preparations, food supplements, and systemic anti-infectives; API (active pharmaceutical ingredients) manufacturing; veterinary pharmaceuticals; and other consumer products. DEVARGE serves as the integrated R&D center, while Devakademi provides internal learning and development programs.
Differentiator
Problem solved
Functional benefit
Brands
- Saba: Healthcare brand with established presence and diverse product portfolio.
- Devatis
- Vetas
- Boğaziçi Kolonyaları
Products and services
- Human Pharmaceuticals
- Active Pharmaceutical Ingredients (API)
- Veterinary Pharmaceuticals (Vetas)
- Contract Manufacturing Services
- Consumer Products (Boğaziçi Kolonyaları)
Quantifiable outcome
- 1,863 product registrations across 86 countries
- +3 more outcomes
Companies that use Deva
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Deva technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature5 records
Deva partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- TraceLinkcoreDevatis, the U.S. affiliate of Deva Holding, implemented TraceLink's Multienterprise Information Network Tower (MINT) to replace fragmented EDI integrations with a network-based order-to-cash model. Enables real-time transaction exchange with wholesalers, 3PL providers, and other trading partners through a single link. Reduces new partner onboarding timelines from months to as little as three days. Establishes data foundation for future AI agent-driven automation including price validation, order monitoring, shipment reconciliation, and anomaly detection.
- Devatis SubsidiariescoreInternational operations managed through Devatis subsidiaries including Devatis Ltd, Devatis GmbH, Devatis Inc, Devatis AG, Devatis de Mexico S.DE RL. DE C.V., Devatis Pty Ltd, Devatis Canada Inc., Devatis d.o.o. Beograde, Devatis B.V., Devatis LLC, and Devatis UK Ltd. These entities manage commercial operations and expand presence across global pharmaceutical markets.
- Saba İlaç Sanayi ve Ticaret A.Ş.coreSaba brand operates under the DEVA ecosystem with an established presence in healthcare and a strong diverse product portfolio. Philipp Haas serves as Chairman of the Board of Saba İlaç Sanayi ve Ticaret A.Ş.
- VetascoreAnimal health portfolio under the DEVA ecosystem delivering reliable solutions supporting disease prevention and treatment. Vetas joined DEVA Holding in 2017.
- Boğaziçi KolonyalarıminorConsumer product brand combining traditional cologne heritage with modern manufacturing, representing quality and trust.
- United NationscoreDEVA became a registered supplier of the United Nations, enabling supply of pharmaceutical products to UN procurement channels.
- International Distribution PartnerscoreExtensive international distribution network bringing DEVA products to healthcare professionals and patients across different geographies. Operations in highly regulated markets including USA, Germany, UK, and Switzerland.
Scale indicators15 records
Recent moves14 records
Expansion highlights6 records
Deva competitors and assessment
Company assessmentBroad incumbents
- Sandoz (Novartis): Global generic and biosimilar powerhouse spun out of Novartis with a vertically integrated structure and strong biosimilar pipeline. Comparable to DEVA across generic finished doses, APIs, and biosimilars, with far deeper commercial reach in the US and EU.
- Viatris: Global generics manufacturer formed from Mylan and Upjohn with broad therapeutic coverage and worldwide distribution. Comparable to DEVA as a finished-dose generics competitor with established presence across both emerging and regulated markets.
- Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with a vertically integrated API-to-finished-dose model and global distribution across 60+ markets. Directly comparable to DEVA in generic finished doses and APIs, though at materially larger scale and broader therapeutic coverage.
Direct peers
- Bilim Pharmaceuticals: Major Turkish generic pharmaceutical manufacturer with domestic manufacturing and broad therapeutic-area portfolio. Direct domestic competitor to DEVA in the Turkish generics market.
- Aurobindo Pharma: Indian vertically integrated generic and API manufacturer with strong US FDA footprint and global distribution. Closely comparable to DEVA in API + finished-dose model, export-heavy orientation, and regulated-market focus.
- Hikma Pharmaceuticals: MENA-headquartered generic pharmaceutical manufacturer with strong US FDA approved manufacturing and broad therapeutic-area coverage. Comparable to DEVA in regulated-market generic finished doses, MENA + emerging market distribution, and FDA-compliant manufacturing.
- Dr. Reddy's Laboratories: Indian generic and API manufacturer with branded generics across multiple therapeutic areas and significant presence in regulated markets. Comparable to DEVA in finished-dose generics, API exports, and emerging-market leadership.
- Abdi İbrahim: Turkey's largest domestic pharmaceutical company, offering branded generics and consumer health products with manufacturing and R&D in Turkey. Closest direct domestic peer to DEVA, competing in the same Turkish market and overlapping therapeutic areas.
- Zentiva: European-headquartered generic pharmaceutical manufacturer with vertically integrated operations and strong presence in CEE and Western Europe. Directly comparable to DEVA in generic finished doses and EU regulatory footprint; Philipp Haas previously consulted for its predecessor Slovakopharma.
Regional players
- Eczacıbaşı Group (pharmaceutical operations): Diversified Turkish conglomerate with consumer-health and pharmaceutical operations serving primarily the Turkish and regional markets. Comparable as a Turkish pharmaceutical operator with adjacent consumer-health exposure to DEVA's Saba and Boğaziçi Kolonyaları businesses.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Deva social profiles
Digital presenceDeva compliance and trust
Trust signalCompliance5 records
Deva financial estimates
Financial estimateRevenue estimate
Valuation estimate
Deva leadership team
Management profileNumber of profiles
Profiles6 records
Deva subsidiaries and ownership
Company hierarchySubsidiaries15 records
Deva funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Deva M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Deva
What does Deva do?
DEVA Holding is a vertically integrated pharmaceutical manufacturer that develops, produces, and markets human pharmaceuticals across 15 therapeutic areas, active pharmaceutical ingredients (APIs), veterinary medicines, and consumer health products. The company operates four manufacturing facilities compliant with US FDA and EU GMP standards, conducts R&D through its DEVARGE center with 400+ researchers, and exports products to 60+ countries with 1,863 product registrations across 86 countries. Additional revenue lines include contract manufacturing services and licensing/co-development partnerships with international pharmaceutical firms.
Is Deva a public or private company?
Deva is a public company. It is classified as public and is currently operating.
When was Deva founded?
Deva was founded in 1958. It employs 1,001 to 5,000 people.
Where is Deva based?
Deva is headquartered in Istanbul.
How does Deva make money?
Four revenue lines are on record. Pharmaceutical Products are the primary driver. The others are contract Manufacturing Services, active Pharmaceutical Ingredients (API) and licensing and Co-development.
Who are Deva's main competitors?
Broad incumbents on record are Sandoz (Novartis), Viatris and Teva Pharmaceutical Industries. Direct peers are Bilim Pharmaceuticals, Aurobindo Pharma, Hikma Pharmaceuticals, Dr. Reddy's Laboratories, Abdi İbrahim and Zentiva. Eczacıbaşı Group (pharmaceutical operations) is listed as a regional player.
Does Deva have an API?
No public API is recorded for Deva.
What industry is Deva in?
Deva's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ), with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 325412 and its SIC code is 2834.